Crystax Pharmaceuticals is a leading structure-based drug discovery company. We identify and develop new lead compounds by a combination of structural and biophysical techniques that accelerate the process of drug discovery and bring higher quality molecules to the market. Core areas of expertise are: X-ray Crystallography, NMR, Fragment Screening and Hit Optimization by biophysical analysis and computational chemistry.

 

Our unique expertise accelerates the drug discovery process.


Crystax pursues in-house drug discovery projects, mainly focused in the oncology area. At the same time, Crystax provide its expertise to pharmaceutical partners and participates in European Projects and Government funded initiatives in collaboration with National Research Centers.

 

   
 
 
Located in Barcelona, Crystax was founded in 2002 as a biotech company dedicated to structure-base drug discovery...
See More...
 

Chaperones: An emerging concept for cancer treatment consists of inhibiting processes that, though not specifically involved in cancer development...

See More...
 
Events & News

23th November, 2007

Crystax holds an International Meeting on brain cancer

15th November, 2007

Enisa award to Crystax as the most innovative company in Life Sciences

July, 2007

Dr. José Maria Palacios as new President of the Scientific Advisor Board

17th March , 2007
Crystax wins the award "Emprenedor XXI" sponsored by "La Caixa" to the enterprise with more growing potential

March, 2006
CENIT approves the funding to the project of R&D Genius Pharma

February, 2006
New DNA structure allows the design of new pharmacological agents


30 September, 2005
Crystax Pharmaceuticals closes financing round


9 September, 2005
SERVIER and Crystax Pharmaceuticals sign research collaboration


23rd February, 2005
Spanish Esteve and other three laboratories form a partnership


17 December, 2004
Crystax Pharmaceuticals and
Uriach sign a contract for new
anti-inflammatory drug development